Shan Lu

Shan Lu holds extensive financial management experience, currently serving as VP of Finance at Uncommon Cures since February 2024. Previously, Shan worked as Group Financial Controller at Barinthus Biotherapeutics and ReveraGen BioPharma Inc., along with Controller roles at Biodenta North America, LLC. Earlier career highlights include a Financial Analyst position at Legal & General America and an Auditor role at Deloitte & Touche, where participation in significant IPO engagements was notable. Educational qualifications include an MBA in Accounting and Finance from American University's Kogod School of Business. Shan's expertise encompasses budgeting, compliance with financial regulations, financial reporting, team development, and implementation of accounting policies and ERP systems.